Stevens First Principles Investment Advisors’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Stevens First Principles Investment Advisors’s Portfolio ICPT Stock Details ICPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-150	Closed	-$42K	–	242
2015 Q1	$42K	Sell	150 -650	-81%	-$141K	0.03%	138
2014 Q4	$125K	Buy	800 +530	+196%	+$97.9K	0.08%	95
2014 Q3	$64K	Buy	270 +120	+80%	+$30.6K	0.04%	138
2014 Q2	$35K	Buy	+150	New	+$39.5K	0.02%	160

Other funds holding ICPT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Stevens First Principles Investment Advisors's ICPT Position: Q2 2015 in Review

Stevens First Principles Investment Advisors sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q2 2015, closing a stake of 150 shares — an estimated $42K sold.

Stevens First Principles Investment Advisors first reported a position in ICPT in Q2 2014 and held it in 4 quarters. The position peaked at $125K in Q4 2014. 191 funds tracked by Wall St. Rank hold ICPT as of Q2 2015.

Stevens First Principles Investment Advisors reported no remaining Intercept Pharmaceuticals, Inc. position as of Q2 2015 after selling out during the quarter.
Stevens First Principles Investment Advisors sold 150 Intercept Pharmaceuticals, Inc. shares in Q2 2015, an estimated $42K.
Stevens First Principles Investment Advisors first reported a position in Intercept Pharmaceuticals, Inc. in Q2 2014 and held it in 4 quarters.
Stevens First Principles Investment Advisors's Intercept Pharmaceuticals, Inc. position peaked at $125K in Q4 2014.
191 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q2 2015.

Based on Stevens First Principles Investment Advisors's 13F filing for Q2 2015, filed 5 Aug 2015.